Using stem cell transplants to treat severe autoimmune diseases in young patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial evaluates the effectiveness of autologous stem cell transplantation (ASCT) combined with high-dose immunosuppressive therapy in children and young adults suffering from severe systemic lupus erythematosus and systemic sclerosis. The approach aims to eliminate the harmful autoreactive immune system and potentially reset the immune response. By targeting these life-threatening autoimmune diseases, the study seeks to provide a new treatment avenue for patients who have not responded to conventional therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 8 ≤ 25 years at time of enrollment.
2. Severe systemic sclerosis or systemic lupus erythematosus based on specific criteria
3. Adequate organ function status
4. No active, untreated infections.

Exclusion Criteria:

1. Previous hematopoietic stem cell transplant (HSCT) or solid organ transplant
2. Pregnancy
3. Ongoing participation in a clinical trial testing an investigational drug or ongoing receipt of disallowed disease modifying anti-rheumatic drugs (DMARD)
4. Severe comorbidity that jeopardizes the ability of the subject to tolerate therapy

Where it's running

• Children's Hospital of Philadelphia
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Caitlin Elgarten, MD — Children's Hospital of Philadelphia
• Study coordinator: Patricia M Hankins
• Email: HANKINSP@chop.edu
• Phone: (215) 590-5168

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Test of HBM7020 in healthy adults and adults with autoimmune diseases

  This first-in-human study tests whether HBM7020 is safe and how it acts in the body for people with autoimmune diseases like RA, SLE, Sjögren's, and SSc compared with healthy volunteers.

  Recruiting Phase 1 Otsuka Pharmaceutical Development & Commercialization, Inc. · Brisbane, Queensland · NCT07649265

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Immun4Cure Cohort of Autoimmune Diseases

  A long-term, 500-person database and biobank is being built to study autoimmune diseases like RA, SLE, and scleroderma, plus healthy adults, using deep profiling and regular follow-ups over five years.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07515638

• Anti-CD19/BCMA U CAR-T cell therapy for relapsed or refractory autoimmune diseases

  This pilot will test whether anti-CD19/BCMA U CAR-T cells can help adults with relapsed or refractory autoimmune diseases such as SLE, systemic sclerosis, Sjögren's syndrome, and rheumatoid arthritis.

  Recruiting Early Phase 1 Changhai Hospital · Shanghai · NCT07246096

• Imaging in Inflammatory Heart Diseases linked to autoimmune disorders

  This study tests how well multimodality imaging (CMR, echocardiography, and PET) detects inflammation in people with suspected inflammatory heart or autoimmune rheumatic diseases.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07077304

• Investigating Neutrophil Extracellular Traps in Systemic Sclerosis

  This study is trying to understand how certain immune cells called Neutrophil Extracellular Traps might be linked to the symptoms and complications of Systemic Sclerosis in patients.

  Recruiting CHU de Reims · Reims · NCT06462768

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.